Search
sofpironium; ACTUAT sofpironium (Sofdra)
Indications:
- treatment of primary axillary hyperhidrosis in adults & pediatric patients >=9 years
Contraindications:
- conditions exacerbated by anticholinergic agents
- glaucoma, paralytic ileus, severe ulcerative colitis, toxic megacolon, myasthenia gravis, Sjogren's syndrome
Dosage:
- 1 pump underarm daily
Topical gel: 12.45% of sofpironium
Pharmacokinetics:
- metabolized by nonenzymatic hydrolysis, CYP2D6 & CYP3A4 with glycine conjugation
- does not affect QTc
Adverse effects:
- anticholinergic effects
- urinary retention
- blurred vision
- application site erythema,
- mydriasis
- xerostomia (dry mouth)
Drug interactions:
- anticholinergic agents
- strong inhibitors of CYP2D6 (prolongs 1/2 life of sofpironium)
Mechanism of action:
- competitive inhibitor of muscarinic receptors associated with sweat glands
Interactions
drug adverse effects of parasympatholytics
General
parasympatholytic (anticholinergic, antimuscarinic agent)
dermatologic agent
topical agent
Database Correlations
PUBCHEM correlations
References
- HIGHLIGHTS OF PRESCRIBING INFORMATION
SOFDRA (sofpironium) topical gel, 12.45%
https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217347s000lbl.pdf